SCHEMBL243401

SCHEMBL243401

CC(C)(C)OC(=O)Nc1ccc(C(=O)O)cc1

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP17A1 P05093 2/20 0.56
NAMPT P43490 1/20 0.56
EPHX2 P34913 1/20 0.56
NR1H4 Q96RI1 1/20 0.56
MAPT P10636 1/20 0.55
PSMB8 P28062 1/20 0.49
CA12 O43570 3/20 0.47
CA9 Q16790 3/20 0.47
CA2 P00918 2/20 0.47
ALDH1A1 P00352 1/20 0.47
PTPN11 Q06124 1/20 0.47
CD274 Q9NZQ7 1/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
MITF O75030 1/20 0.46
CA1 P00915 1/20 0.46
PRMT1 Q99873 1/20 0.45
PTGDR2 Q9Y5Y4 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3360413 0.95 CYP17A1 (0.63) CYP17A1NAMPTEPHX2NR1H4MAPT
SCHEMBL22461618 0.94 NAMPT (0.65) CYP17A1NAMPTEPHX2NR1H4MAPT
SCHEMBL22461360 0.94 NAMPT (0.65) CYP17A1NAMPTEPHX2NR1H4MAPT
Aminobenzoic Acid SCHEMBL6627812 0.92 CYP17A1 (0.50) CYP17A1NAMPTEPHX2NR1H4MAPT
SCHEMBL3020158 0.91 PTPN11 (0.59) CYP17A1NAMPTEPHX2NR1H4MAPT
Toluene SCHEMBL27667509 0.91 NAMPT (0.52) CYP17A1NAMPTEPHX2NR1H4MAPT
SCHEMBL13055402 0.89 CYP17A1 (0.59) CYP17A1NAMPTPSMB8CA12CA9
SCHEMBL31452339 0.88 KMT2A (0.51) CYP17A1NAMPTEPHX2NR1H4MAPT
SCHEMBL12637634 0.87 CYP17A1 (0.57) CYP17A1NAMPTPSMB8CA12CA9
SCHEMBL16665197 0.86 CYP17A1 (0.53) CYP17A1NAMPTMAPTPSMB8CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1051 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119039253-A Furanaromatic diamide neuraminidase inhibitor and preparation method and application thereof 上海应用技术大学 2024-11-29 CN claimed
CN-118374257-B Solvent-free two-component polyurethane adhesive and preparation method thereof 烟台云泷化学制品有限公司 2024-08-16 CN claimed
CN-118374257-A Solvent-free two-component polyurethane adhesive and preparation method thereof 烟台云泷化学制品有限公司 2024-07-23 CN claimed
CN-117534721-A Preparation method of hederagenin derivative 烟台大学 2024-02-09 CN claimed
CN-116924924-A Synthetic method of tetracaine 山东创新药物研发有限公司 2023-10-24 CN claimed
CN-116874803-A Antibacterial dendritic polyester polymer and preparation method and application thereof 清华大学深圳国际研究生院 2023-10-13 CN claimed
CN-115611814-A Compound containing 2-aminoimidazole ring and preparation method and application thereof 烟台新药创制山东省实验室 2023-01-17 CN claimed
CN-115160612-A Synthesis process and application of polyethylene mildew-proof preservative film 袁旭 2022-10-11 CN claimed
CN-114539195-A Ludartin derivative, pharmaceutical composition thereof, preparation method and application thereof 中国科学院昆明植物研究所 2022-05-27 CN claimed
CN-108929433-B Preparation method of star polymer with cyclodextrin at tail end 中北大学 2020-05-15 CN claimed
CN-108929433-A A kind of end is the preparation method of the star polymer of cyclodextrin 中北大学 2018-12-04 CN claimed
WO-2026104812-A1 RAB27 INHIBITORS IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) 2026-05-21 WO disclosed
EP-4725560-A2 ANTI-B7H3 ANTIBODIES FOR THE PREPARATION OF ANTIBODY DRUG CONJUGATES (ADCS) OF KSP INHIBITORS Bayer Pharma Aktiengesellschaft (DE) 2026-04-15 EP disclosed
US-12577200-B2 High-throughput method to rapidly add chemical moieties to a small molecule library MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2026-03-17 US disclosed
US-12528785-B2 MDM2 degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2026-01-20 US disclosed
WO-1993016073-A1 PIPERAZINE AND PIPERIDINE DERIVATIVES, AND THEIR USE AS ANTIPSYCHOTICS THE WELLCOME FOUNDATION LIMITED (GB) 1993-08-19 WO disclosed
EP-0386644-A2 Reagents for the determination of drugs F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1990-09-12 EP disclosed
EP-0091240-B1 ENZYME DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM BEECHAM GROUP PLC (GB) 1985-12-27 EP disclosed
US-4507283-A STREPTOKINASE-HUMAN PLASMINOGEN ACTIVATOR COMPLEX BLOCKED BY A 2- OR 4-AMINOBENZOYL GROUP; ANTICOAGULANT BEECHAM GROUP P.L.C. (GB) 1985-03-26 US disclosed
EP-0091240-A2 Enzyme derivatives, process for preparing them and pharmaceutical compositions containing them BEECHAM GROUP PLC (GB) 1983-10-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12528785-B2 MDM2 degraders and uses thereof MDM2, ADRM1, RBX1 CYP17A1 2650/4885NAMPT 4861/4885EPHX2 2368/4885
US-12577200-B2 High-throughput method to rapidly add chemical moieties to a small molecule library CBR3, CBR1, NR2E3 CYP17A1 1276/4885NAMPT 3064/4885EPHX2 416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.